Drugmakers Agree To Supply Additional RSV Immunization Doses To US Market

Reuters (12/14, Hunnicutt, Erman, Jackson) reports, “The makers of a respiratory syncytial virus immunization for infants that has been in tight supply will deliver an additional 230,000 doses in January, the White House said on Thursday, after U.S. government officials met with the companies to discuss meeting winter demand.” The new doses of the RSV shot Beyfortus (nirsevimab) “are from supply originally intended for the Southern Hemisphere RSV season, which will be replenished before that season starts later next year, a Sanofi spokesperson said.” The Hill (12/14, Weixel) also covers the story.